In an ever evolving and ever changing landscape, preclinical formulation is an exciting area for drug product development. Formulation design is especially important in poorly bioavailable clinical candidates. To give meaningful results, the compound has to be dissolved as the same excipients being used in order to improve solubility or it may give unwanted effects and therefore disproportionate results.

In response, we wanted to share a presentation deck titled “Selection of clinically relevant forms & formulations using in vitro analysis & preclinical models” from Phil Snyder at Vertex Pharmaceuticals. This talk was given during one of our previous Controlled & Modfied Drug Release Summits last year. This presentation discusses using preformulation as a tool to accelerate clinical evaluation of medicines, also the physico-chemical analysis of interactions driving bioavailability and lastly the mechanisms at play in the interactions between
drugs and biological milieux.

Scroll through the presentation below……

2021 Global Drug Bioavailability Enhancement Summit

(Nov 3 - 4, 2021)

 

Interested to improve the performance of your drug products? Learn 2 years of new drug product development approaches at the 2021 Global Drug Bioavailability Enhancement Virtual Summit this November.

Join 100's of leading drug delivery, formulation and development experts and hear 25+ expert sessions. Gain over 2 years worth of new drug product development strategies, formulation approaches, delivery technologies and regulatory updates while decreasing drug product time-to-market in just 2 short days (all available on-demand)!

Save over 10% on attendance registration before October 30th, 2021 (Only $449). Likewise, have a platform technology you would like to explore showcasing to the wider audience this November? Reach out below to find out remaining opportunities.

2021 On-Demand Summits Available for Purchase

(Limited time - Only $299)

Pin It on Pinterest

Share This

Share this with a friend or colleague!